BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1228 related articles for article (PubMed ID: 9270017)

  • 21. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
    Zhang L; Kharbanda S; Hanfelt J; Kern FG
    Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.
    Vickers PJ; Dickson RB; Shoemaker R; Cowan KH
    Mol Endocrinol; 1988 Oct; 2(10):886-92. PubMed ID: 3185565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
    Herman ME; Katzenellenbogen BS
    J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression.
    Clarke R; Skaar T; Baumann K; Leonessa F; James M; Lippman J; Thompson EW; Freter C; Brunner N
    Breast Cancer Res Treat; 1994; 31(2-3):237-48. PubMed ID: 7881102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
    Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
    Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.
    Brünner N; Boulay V; Fojo A; Freter CE; Lippman ME; Clarke R
    Cancer Res; 1993 Jan; 53(2):283-90. PubMed ID: 8380254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
    Lykkesfeldt AE; Larsen SS; Briand P
    Int J Cancer; 1995 May; 61(4):529-34. PubMed ID: 7759159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of acquired antiestrogen resistance and its management in breast cancer].
    Iino Y; Maemura M; Morishita Y
    Nihon Rinsho; 1997 May; 55(5):1149-54. PubMed ID: 9155167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.
    Gottardis MM; Ricchio ME; Satyaswaroop PG; Jordan VC
    Cancer Res; 1990 Jun; 50(11):3189-92. PubMed ID: 2334915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media.
    Pratt SE; Pollak MN
    Cancer Res; 1993 Nov; 53(21):5193-8. PubMed ID: 7693333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
    Arteaga CL; Koli KM; Dugger TC; Clarke R
    J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.